Ben Trotman, 43, was diagnosed with glioblastoma in October 2022 and was given an immunotherapy drug as part of a world-first clinical trial. Two years and eight months later, his scans show no signs of the tumour, indicating a significant improvement in his health.
Glioblastoma, the deadliest form of brain cancer, typically has a mortality rate within 12-18 months. Mr Trotman’s remarkable recovery has led to the NHS recruiting 16 people over 18 months to participate in a new immunotherapy trial in honour of Baroness McDonagh, who passed away from the disease.
The University College London Hospital (UCLH) conducted this trial after a previous one on the same drug was halted due to recruitment issues. This new trial aims to build upon Mr Trotman’s success and explore the potential benefits of immunotherapy for glioblastoma patients.
Source: https://www.telegraph.co.uk/news/2025/07/21/brain-cancer-vanish-after-world-first-clinical-trial